Link Technologies Announces Expansion into the Far East with New Distributor
News Jun 13, 2013
Link Technologies Ltd has announced Zirench Technology Co. Ltd as distributor in China, the first Asian distributor for its comprehensive range of products.
Located in Dalian City, Zirench Technology will represent Link Technologies in China, expanding their reach across the country and providing invaluable local support for customers.
The appointment of Zirench Technology is the first signing of multiple, upcoming distributorship agreements in the Far East, and is testament to Link Technologies’ on-going strategic development and growth.
As an ISO 9001:2008 certified supplier of products for oligonucleotide synthesis, Link Technologies is committed to providing all customers with high purity, reliable oligo precursors and reagents, which can now extend to customers in China, thanks to Zirench Technology.
Commenting on the new distributor agreement, Dr John Bremner, CEO at Link Technologies, said: “We are working hard to effectively deliver our products to customers in research and industrial institutions in Asia and other parts of the world, where easily accessible local support and expertise is very important. We are delighted that this deal with Zirench boosts this strategy.”
Dr Victor Liu, Commercial Manager at Zirench Technology, added “Our aim is to offer our customers laboratory instruments, supplies and biological agents of world-class quality. As such, we were keen to act on behalf of Link Technologies, to raise awareness of and distribute their high quality oligo precursor products across China.”
Providing a broad catalogue of reagents for DNA, RNA and PNA synthesis, Link Technologies has particular expertise in the manufacture of modified nucleic acid products, often unavailable elsewhere.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.